Alpine Global Management LLC bought a new stake in Ambrx Biopharma during the fourth quarter worth about $106,000.

Source: https://www.americanbankingnews.com/2023/09/21/cormorant-asset-management-lp-buys-751233-shares-of-ambrx-biopharma-inc-nyseamam-stock.html

Arbutus Biopharma (NASDAQ:ABUS) Upgraded to “Buy” by StockNews.

Source: https://www.americanbankingnews.com/2023/05/06/arbutus-biopharma-nasdaqabus-upgraded-to-buy-by-stocknews-com.html

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines.

Source: https://www.etfdailynews.com/2023/12/09/benitec-biopharma-nasdaqbntc-stock-crosses-above-50-day-moving-average-of-3-35/

BlackRock Inc. lifted its position in shares of Connect Biopharma by 4.3% during the first quarter.

Source: https://www.etfdailynews.com/2023/02/10/connect-biopharma-nasdaqcntb-pt-lowered-to-7-00-at-svb-leerink/

Connect Biopharma has a twelve month low of $0.53 and a twelve month high of $1.58.

Source: https://www.etfdailynews.com/2023/10/12/connect-biopharma-holdings-limited-nasdaqcntb-sees-large-growth-in-short-interest/

Finally, JMP Securities reaffirmed a market outperform rating and set a $6.00 price objective on shares of Arbutus Biopharma in a report on Wednesday, March 29th.

Source: https://www.etfdailynews.com/2023/04/06/arbutus-biopharma-nasdaqabus-earns-buy-rating-from-hc-wainwright/

He was most recently executive vice-president and chief financial officer at Starpax Biopharma.

Source: https://halifax.citynews.ca/2023/12/12/transat-at-names-jean-francois-pruneau-as-next-chief-financial-officer/

Its Laboratory Products and Biopharma Services segment provides laboratory products, laboratory chemicals, research and safety market channel, and pharma services and clinical research.

Source: https://www.etfdailynews.com/2023/11/19/comparing-angle-otcmktsanpcy-thermo-fisher-scientific-nysetmo/

Moneta Group Investment Advisors LLC raised its position in Arbutus Biopharma by 49.1% during the first quarter.

Source: https://www.etfdailynews.com/2023/09/16/arbutus-biopharmas-abus-buy-rating-reiterated-at-hc-wainwright/

On Monday, April 17th, Cormorant Asset Management, Lp bought 562,121 shares of Ambrx Biopharma stock.

Source: https://www.dailypolitical.com/2023/04/20/insider-buying-ambrx-biopharma-inc-nyseamam-major-shareholder-purchases-951909-shares-of-stock.html

Point72 Middle East FZE purchased a new stake in shares of Theravance Biopharma during the fourth quarter valued at approximately $41,000.

Source: https://www.etfdailynews.com/2023/08/01/arizona-state-retirement-system-sells-1534-shares-of-theravance-biopharma-inc-nasdaqtbph/

Receive News & Ratings for Hansa Biopharma AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hansa Biopharma AB (publ) and related companies with MarketBeat.

Source: https://www.etfdailynews.com/2023/11/20/reviewing-hansa-biopharma-ab-publ-otcmktshnsbf-and-autolus-therapeutics-nasdaqautl/

Receive News & Ratings for Hansa Biopharma AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hansa Biopharma AB (publ) and related companies with MarketBeat.

Source: https://www.etfdailynews.com/2023/11/20/reviewing-hansa-biopharma-ab-publ-otcmktshnsbf-and-autolus-therapeutics-nasdaqautl/

Theravance Biopharma had a negative return on equity of 22.72% and a net margin of 1,803.67%.

Source: https://www.etfdailynews.com/2023/08/01/arizona-state-retirement-system-sells-1534-shares-of-theravance-biopharma-inc-nasdaqtbph/